Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Novo Nordisk latest drugmaker to drop gender goals in US
    Finance

    Novo Nordisk latest drugmaker to drop gender goals in US

    Published by Global Banking & Finance Review®

    Posted on May 7, 2025

    1 min read

    Last updated: January 24, 2026

    Novo Nordisk latest drugmaker to drop gender goals in US - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Novo Nordisk ceases US gender representation goals due to legal shifts, joining other European drugmakers in adjusting diversity policies.

    Novo Nordisk Ends US Gender Goals Amid Policy Changes

    By Jacob Gronholt-Pedersen and Maggie Fick

    COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.

    "While Novo Nordisk maintains our global aspiration of a minimum 45% representation for each gender by the end of 2025, Novo Nordisk's operations in the U.S. will no longer participate in this global initiative due to evolving legal requirements," the company said in its first-quarter earnings statement.

    Following Trump taking office in January and up to Wednesday, the Danish company had, when asked, affirmed it would not change its stance on the importance of a diverse workforce.

    With the changed stance for its U.S. business, Novo joins peer European drugmakers who have acted to avoid potential penalties from recent U.S. executive orders.

    In March, Swiss drugmaker Roche abandoned global diverse workforce targets and compatriot Novartis ended its use of diverse panels for U.S. hiring. In February, GSK announced it will no longer set diversity targets.

    (Reporting by Jacob Gronholt-Pedersen and Maggie Fick, Editing by Louise Heavens)

    Key Takeaways

    • •Novo Nordisk drops gender goals for US operations.
    • •Decision follows Trump's executive orders on diversity.
    • •Global gender representation target remains at 45%.
    • •Other European drugmakers have made similar changes.
    • •US legal requirements prompt policy adjustments.

    Frequently Asked Questions about Novo Nordisk latest drugmaker to drop gender goals in US

    1What is the main topic?

    The article discusses Novo Nordisk's decision to drop gender representation goals in the US due to changing legal requirements.

    2Why did Novo Nordisk change its policy?

    Novo Nordisk altered its policy in response to executive orders by President Trump affecting diversity initiatives.

    3Which other companies have made similar changes?

    Swiss drugmaker Roche and Novartis, as well as GSK, have also adjusted their diversity policies in the US.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    View All Finance Posts
    Previous Finance PostGerman firms slash investment plans in Hungary amid weak outlook
    Next Finance PostUK financial watchdog consults on steps to simplify mortgage rules